The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder.
Amyotrophic lateral sclerosis
Diagnosis
Nanomedicine
Neurological disorder
Pathophysiology
Therapeutics
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
received:
19
08
2021
revised:
10
11
2021
accepted:
11
11
2021
pubmed:
22
11
2021
medline:
11
1
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurological disease affecting both upper and lower motor neurons. In the United States alone, there are 16,000-20,000 established cases of ALS. The early disease diagnosis is challenging due to many overlapping pathophysiologies with other neurological diseases. The etiology of ALS is unknown; however, it is divided into two categories: familial ALS (fALS) which occurs due to gene mutations & contributes to 5-10% of ALS, and sporadic ALS (sALS) which is due to environmental factors & contributes to 90-95% of ALS. There is still no curative treatment for ALS: palliative care and symptomatic treatment are therefore essential components in the management of these patients. In this review, we provide a panoramic view of ALS, which includes epidemiology, risk factors, pathophysiologies, biomarkers, diagnosis, therapeutics (natural, synthetic, gene-based, pharmacological, stem cell, extracellular vesicles, and physical therapy), controversies (in the clinical trials of ALS), the scope of nanomedicine in ALS, and future perspectives.
Identifiants
pubmed: 34801512
pii: S0024-3205(21)01143-7
doi: 10.1016/j.lfs.2021.120156
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
120156Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.